Dare Bioscience (DARE)
(Delayed Data from NSDQ)
$3.55 USD
+0.15 (4.41%)
Updated Aug 29, 2024 04:00 PM ET
After-Market: $3.46 -0.09 (-2.54%) 5:26 PM ET
3-Hold of 5 3
F Value B Growth A Momentum C VGM
Balance Sheet
Fiscal Year End for Dare Bioscience, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 10 | 35 | 52 | 5 | 5 |
Receivables | 1 | 2 | 1 | 0 | 1 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 6 | 7 | 2 | 2 | 1 |
Total Current Assets | 18 | 43 | 55 | 7 | 6 |
Net Property & Equipment | 1 | 0 | 0 | 0 | 0 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 2 | 1 | 0 | 1 | 1 |
Total Assets | 21 | 44 | 56 | 8 | 7 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 3 | 2 | 2 | 1 | 1 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 3 | 11 | 3 | 3 | 2 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 14 | 18 | 11 | 3 | 2 |
Total Current Liabilities | 20 | 32 | 16 | 8 | 6 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 1 | 1 | 1 | 1 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 4 | 0 | 0 | 0 | 1 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 26 | 33 | 17 | 9 | 7 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 167 | 153 | 149 | 70 | 45 |
Retained Earnings | -171 | -141 | -110 | -71 | -44 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | -5 | 11 | 39 | -1 | 0 |
Total Liabilities & Shareholder's Equity | 21 | 44 | 56 | 8 | 7 |
Total Common Equity | -5 | 11 | 39 | -1 | 0 |
Shares Outstanding | 8.20 | 7.00 | 6.30 | 3.40 | 1.60 |
Book Value Per Share | -0.62 | 1.59 | 6.15 | -0.34 | 0.28 |
Fiscal Year End for Dare Bioscience, Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 16 | 4 | 10 | 14 | 13 |
Receivables | 1 | 1 | 1 | 1 | 1 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 4 | 5 | 6 | 7 | 8 |
Total Current Assets | 21 | 10 | 18 | 22 | 22 |
Net Property & Equipment | 0 | 0 | 1 | 0 | 0 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 1 | 1 | 2 | 3 | 1 |
Total Assets | 24 | 13 | 21 | 25 | 23 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 2 | 4 | 3 | 5 | 7 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 1 | 1 | 3 | 5 | 4 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 11 | 12 | 14 | 16 | 14 |
Total Current Liabilities | 15 | 18 | 20 | 26 | 25 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 1 | 1 | 1 | 1 | 1 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 4 | 4 | 0 | 0 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 21 | 24 | 26 | 27 | 26 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 168 | 167 | 167 | 164 | 156 |
Retained Earnings | -165 | -178 | -171 | -166 | -158 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 3 | -11 | -5 | -2 | -3 |
Total Liabilities & Shareholder's Equity | 24 | 13 | 21 | 25 | 23 |
Total Common Equity | 3 | -11 | -5 | -2 | -3 |
Shares Outstanding | 8.40 | 8.30 | 8.20 | 7.30 | 7.10 |
Book Value Per Share | 0.32 | -1.33 | -0.62 | -0.31 | -0.38 |